Psychiatry · Year 2 · from Psychiatry
Case 2: Treatment-Resistant Schizophrenia - Clozapine Indication
Patient Presentation
Demographics: 38-year-old female
Chief Complaint: "The CIA is still monitoring me. The medications don't work."
History of Present Illness: A 38-year-old woman with an 18-year history of schizophrenia is referred for evaluation of treatment-resistant disease. She was first hospitalized at age 20 for a psychotic episode with persecutory delusions and command auditory hallucinations. Since then, she has been hospitalized 12 times and tried multiple antipsychotics: haloperidol (caused severe akathisia), risperidone (partial response, elevated prolactin with galactorrhea), olanzapine (significant weight gain of 40 lbs, developed diabetes), and aripiprazole (inadequate response). Most recently, she completed an 8-week adequate trial of paliperidone 12 mg daily with only partial improvement. She continues to hear voices commanding her to hurt herself (though she has never acted on commands), believes the CIA is monitoring her through her television, and believes her thoughts are being broadcast to others. She lives in a supervised group home and has not been able to work in 15 years. Her current paliperidone has reduced the intensity of hallucinations but has not eliminated them.
Mental Status Examination:
- Appearance: Obese female, casually dressed, appropriate hygiene (with supervision)
- Behavior: Calm, cooperative
- Speech: Low volume, reduced spontaneity
- Mood: "Okay"
- Affect: Blunted, restricted range
- Thought process: Concrete, mildly circumstantial
- Thought content: Persistent persecutory delusions (CIA monitoring), thought broadcasting; command AH present but not acted upon; denies SI/HI
- Insight: Partial - takes medications because told to, not because believes she is ill
- Judgment: Fair with significant support
Previous Medication Trials:
- Haloperidol 20 mg - discontinued due to akathisia
- Risperidone 6 mg x 12 weeks - partial response, prolactin elevation
- Olanzapine 20 mg x 10 weeks - partial response, significant metabolic effects
- Aripiprazole 30 mg x 10 weeks - inadequate response
- Paliperidone 12 mg x 8 weeks (current) - partial response
Diagnosis: Schizophrenia, continuous, treatment-resistant (failed 2+ adequate antipsychotic trials)
Treatment:
- Meets criteria for treatment-resistant schizophrenia - indicated for clozapine trial
- Discussed unique risks of clozapine: agranulocytosis (requires REMS monitoring), seizures, metabolic effects, constipation, sialorrhea
- Obtained baseline: CBC with ANC, metabolic panel, HbA1c, lipid panel, ECG
- Cross-tapered from paliperidone to clozapine with slow titration:
- Started clozapine 25 mg at bedtime
- Increased by 25-50 mg every 3-4 days
- Target dose 300-450 mg/day
- Registered in Clozapine REMS program; weekly ANC monitoring initially
- At 8 weeks on clozapine 350 mg: Significant improvement in positive symptoms
- Voices reduced in frequency and intensity; no longer feels monitored
- First time in 10 years with meaningful symptom reduction
- At 6 months: Able to volunteer at local library, first structured activity in years
- ANC monitoring decreased to biweekly, then monthly as per REMS schedule
- Manages constipation with bowel regimen, sialorrhea with nighttime towel
Clinical Pearl: Clozapine is the only antipsychotic with demonstrated efficacy for treatment-resistant schizophrenia (defined as failure of 2+ adequate antipsychotic trials). It should be offered to all patients meeting this criterion despite monitoring requirements. The REMS program mandates ANC monitoring due to 1% risk of agranulocytosis. Beyond positive symptoms, clozapine is also the most effective antipsychotic for reducing suicidality in schizophrenia. Response rates to clozapine in treatment-resistant patients are approximately 30-60%.